Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

By W. De Roock, D. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, S. Siena, S. Lamba, S. Arena, M. Frattini, H. Piessevaux and 8 more. Journal of the American Medical Association (JAMA), 2010

728 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/84b7091466d8c220d63fcd4e4e2bb3a0182ee113

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. F. McCormick
2. Fortunato Ciardiello

Citations in the corpus

• Dragging ras back in the ring. (2014, background): “This result challenges our understanding of how these Ras mutations actually function in clinical situations (De Roock et al., 2010).”
• Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action (2012, background): “Pharmacogenomic specification is used for a wide range of drugs from antiasthmatics (e.g., montelukast) (32) to cancer therapeutics (e.g., cetuximab) (33).”
• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012, background): “• KRAS codon G13D mutation (5%) does not indicate efficacy of EGFR antibody treatment in KRAS mutant patients [36–38], although data are conflicting [39] [IV, C].”
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (2013, neutral): “Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
• A comprehensive survey of Ras mutations in cancer (2012, neutral): “The beneficial effects of G13D versus G12D mutations as prognostic indicators for anti-EGFR therapy in advanced colorectal cancer are not evident in non–small cell lung cancer (14, 64).”
• Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations (2015, background): “appears that somemutations of KRASmay also be prognostic (20– 25) and predictive (21, 26) in selected settings.”